PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
Daniela Massi(University of Florence), Mario Mandalà(University of Perugia), D. Minocci(University of Florence), Sara Serra(Italian institute for Genomic Medicine), Barbara Merelli(Ospedale Papa Giovanni XXIII), Laura Cattaneo(Ospedale Papa Giovanni XXIII), Gianna Baroni(University of Florence), Valentina Audrito(Italian institute for Genomic Medicine), Eliana Rulli(Mario Negri Institute for Pharmacological Research), Romina Nassini(University of Florence), Davide Brusa(Italian institute for Genomic Medicine), Silvia Deaglio(Italian institute for Genomic Medicine), Elena Tamborini(National Cancer Institute), Roberta Buonincontri(Italian institute for Genomic Medicine), Michela Ciano(Italian institute for Genomic Medicine), Alessandra Carobbio(Ospedale Papa Giovanni XXIII)
Cited by 146
Related Papers
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
|The Journal of Experimental Medicine|2007|2.4k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
|Archives of Pathology & Laboratory Medicine|2020|485
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
WHO classification of skin tumours
|IARC eBooks|2018|422